Prospective Cohort Study of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis Aggravating Extrahepatic Organ Damage
Key facts
- Who runs it
- Beijing Tsinghua Chang Gung Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 36 people enrolled
- Started
- 11 Mar 2025
- Ended
- 21 Nov 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Not applicable- observational study
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- (1) Aged ≥ 18 years; (2) Definite preoperative diagnosis; (3) Scheduled for partial hepatectomy; (4) Voluntarily participate in this study and provide signed informed consent
Who cannot take part
- (1) Patient refusal; (2) Viral hepatitis, including autoimmune hepatitis, alcoholic liver disease or other toxic liver diseases; (3) History of acute or chronic infectious diseases within two weeks prior to blood testing; (4) Pregnancy; (5) Presence of comorbidities that may affect the evaluation of endpoint outcomes; (6) Conditions rendering the patient ineligible for enrollment as judged by the attending physician; (7) Participation in another concurrent study that may interfere with the outcome assessment of this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational prospective cohort study is to explore the impacts and potential molecular mechanisms of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) on extrahepatic organ injury in adult patients scheduled for partial hepatectomy. The main questions it aims to answer are:
Read full original descriptionShow less
Do patients with NAFLD/NASH suffer more severe extrahepatic organ injury compared with patients without NAFLD/NASH? Are inflammatory mediators (IL-2, IL-6, IL-11) associated with the severity of NAFLD/NASH and extrahepatic organ damage?
Researchers will compare the NAFLD/NASH group (n=18) with the non-NAFLD/NASH group (n=18) to see if NAFLD/NASH aggravates extrahepatic organ injury and correlates with elevated levels of serum and urinary inflammatory mediators .
Participants will:
* Provide 3 mL preoperative venous blood sample and 5 mL mid-stream urine sample for detection of inflammatory mediators. * Undergo partial hepatectomy; small pieces of resected liver tissue will be collected for HE staining and Oil-Red-O staining for histopathological evaluation and disease-staging. * Complete routine preoperative baseline assessments including demographic data, medical history, laboratory tests and instrumental examinations. * Receive clinical laboratory and instrumental examinations related to liver and extrahepatic organ function within 7 days after surgery for outcome evaluation.
The 2 groups in the trial
- Participants with NAFLD/NASH(n=18)
Treatment: Not applicable- observational study
- Participants without NAFLD/NASH(n=18)
Treatment: Not applicable- observational study
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 November 2026